Agios Pharmaceuticals, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; standalone fourth-quarter results are not clearly provided in the filing text. Financial amounts below are in U.S. dollars.
Business context
Agios is a single-segment biopharmaceutical company focused on small-molecule medicines for rare diseases. Its lead product, PYRUKYND (mitapivat), was approved in the United States in February 2022 for adults with pyruvate kinase (PK) deficiency; the European Commission and Great Britain authorized it for adult PK deficiency in November and December 2022, respectively. The company is developing mitapivat for thalassemia, sickle cell disease (SCD), and pediatric PK deficiency, alongside AG-946 and a preclinical PAH stabilizer program for phenylketonuria.
Agios sold its oncology business to Servier in March 2021 and reports it as a discontinued operation. In May 2022, it refocused exploratory research on later-stage programs and business development, reducing approximately 45 research roles.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 | Change / context |
|---|---|---|---|
| Revenue | $14.2 million | $0 | 2022 included $11.7 million of net PYRUKYND sales and $2.5 million of milestone revenue from licensing intellectual property for a Friedreich’s ataxia preclinical program. |
| Operating expenses | $403.3 million | $378.4 million | Up $24.9 million, principally higher R&D. |
| Research and development | $279.9 million | $257.0 million | Up $22.9 million as mitapivat, AG-946, and other programs advanced. |
| Selling, general and administrative | $121.7 million | $121.4 million | Broadly unchanged. |
| Loss from continuing operations | $231.8 million | $356.5 million | Improved, primarily due to the 2022 contingent-payment sale gain and other income. |
| Net income (loss) | $(231.8) million | $1.605 billion | 2021 income reflected the oncology-business sale; it is not indicative of recurring profitability. |
| Cash used in operating activities | $309.5 million | $407.3 million | 2021 included $93.2 million used by discontinued operations; 2022 use was from continuing operations. |
At December 31, 2022, cash and cash equivalents were $139.3 million and marketable securities were $957.7 million, totaling approximately $1.10 billion, versus $1.29 billion a year earlier. Cash, cash equivalents, and marketable securities declined by $63.9 million during 2022. Total assets were $1.239 billion, total liabilities $137.9 million, and accumulated deficit $470.6 million. The balance sheet reports no borrowings; lease liabilities were $85.7 million, including current and long-term amounts. Current assets were $832.8 million and current liabilities $62.6 million.
Cost of sales was $1.7 million, but some product manufacturing costs were expensed before approval; a conventional gross margin may therefore not be representative. The filing reports no off-balance-sheet arrangements. Operating lease obligations totaled $99.2 million undiscounted. Agios stated its existing liquidity and anticipated product revenue and interest income were expected to fund its operating plan to cash-flow positivity without additional equity, and that liquidity was sufficient for at least the next 12 months. These are management estimates, not guarantees.
Material changes and unusual items
- On October 27, 2022, Agios sold its rights to future 5% U.S. TIBSOVO royalty payments to Sagard for $131.8 million in cash and recorded a $127.9 million gain. It retained potential vorasidenib milestone and royalty rights.
- Servier paid Agios $9.9 million in 2022 royalties on TIBSOVO U.S. sales, compared with $6.6 million in 2021; those future TIBSOVO royalty rights were sold to Sagard.
- The 2021 oncology-business sale generated approximately $1.8 billion cash at closing and a $1.976 billion after-tax accounting gain. The resulting $1.605 billion 2021 net income contrasts with continuing operating losses.
- Agios recorded $11.3 million of unrealized losses on available-for-sale securities in 2022, included in other comprehensive loss.
- The company had repurchased $802.5 million of stock under its $1.2 billion authorization by year-end 2022; repurchases were paused, with capital allocation prioritized toward pipeline and business-development opportunities.
Outlook, commentary, and risks
- Management’s long-term vision for 2026 is to build a classical hematology franchise, expand the pipeline through internal programs and disciplined licensing or acquisitions, and achieve cash-flow positivity. The company estimated annual average savings of $40–$50 million from its research reorganization between 2023 and 2026.
- At the filing date, management expected enrollment in the two Phase 3 thalassemia trials by mid-2023, to report Phase 2 SCD data and decide on Phase 3 initiation by mid-2023, to enroll at least half of pediatric trial participants by year-end 2023, and to complete AG-946 Phase 2a enrollment and file an investigational new drug application for the PAH program by year-end 2023.
- Servier may owe a $200 million milestone if vorasidenib receives specified FDA approval before January 1, 2027, plus 15% of U.S. net sales of vorasidenib if commercialized. Achievement and royalty amounts are uncertain and depend on clinical, regulatory, and commercial outcomes.
- Principal risks include commercial adoption and reimbursement of newly launched PYRUKYND, clinical-trial outcomes and enrollment, competition, reliance on third-party manufacturers and research organizations, intellectual-property protection, and the possibility that cash needs exceed management estimates. Agios reported that COVID-19 had disrupted some clinical and research activity but had not materially affected supply or financial results through year-end.
- No material legal proceedings were reported. The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; accounting for the Sagard agreement was identified as a critical audit matter.
Important facts for investors to verify
- PYRUKYND sales growth, patient uptake, net pricing, reimbursement, and the distinction between U.S. sales and free-access programs in Europe and Great Britain.
- Cash burn and updated runway assumptions against the stated goal of cash-flow positivity, including whether the projected research savings are realized.
- Results, timelines, and safety findings for mitapivat’s thalassemia, SCD, and pediatric trials and for AG-946 and the PAH program.
- Servier-related contingent proceeds, especially the vorasidenib approval milestone and any subsequent royalties.
- The accounting and cash-flow effects of the Sagard transaction, and the effect of the $802.5 million completed repurchases on capital available for development and business development.